Subscriber access provided by UNIVERSITY OF SOUTH CAROLINA LIBRARIES
Article
Synthesis and functional characterization of novel sialyl LewisX mimic-decorated liposomes for Eselectin-mediated targeting to inflamed endothelial cells Chanikarn Chantarasrivong, Akiharu Ueki, Ryutaro Ohyama, Johan Unga, Shinya Nakamura, Isao Nakanishi, Yuriko Higuchi, Shigeru Kawakami, Hiromune Ando, Akihiro Imamura, Hideharu Ishida, Fumiyoshi Yamashita, Makoto Kiso, and Mitsuru Hashida Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.6b00982 • Publication Date (Web): 13 Feb 2017 Downloaded from http://pubs.acs.org on February 15, 2017
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Molecular Pharmaceutics is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 37
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
Synthesis and functional characterization of novel
2
sialyl LewisX mimic-decorated liposomes for E-
3
selectin-mediated targeting to inflamed endothelial
4
cells
5
Chanikarn Chantarasrivong,‡a Akiharu Ueki, ‡ǁb,c Ryutaro Ohyama,b Johan Unga,†a Shinya
6
Nakamura,d Isao Nakanishi,d Yuriko Higuchi,a Shigeru Kawakami,§a Hiromune Ando,b,c,e Akihiro
7
Imamura,b Hideharu Ishida,b,e Fumiyoshi Yamashita,a Makoto Kiso,b,c,* Mitsuru Hashidaa,c*
8
a Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto
9
University, 46-29 Yoshidashimoadachi-cho, Sakyo-ku, Kyoto 606-8302, Japan.
10
b Department of Applied Bioorganic Chemistry, Gifu University, 1-1 Yanagido, Gifu-shi, Gifu
11
501-1193, Japan.
12
c Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University,
13
Yoshidaushinomiya-cho, Sakyo-ku, Kyoto 606-8501, Japan
14
d Department of Pharmaceutical Sciences, Faculty of Pharmacy, Kindai University, 3-4-1
15
Kowakae, Higashi-Osaka, Osaka 577-8502, Japan
ACS Paragon Plus Environment
1
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 2 of 37
1
e Gifu Center for Highly Advanced Integration of Nano and Life Sciences (G-CHAIN), Gifu
2
University, 1-1 Yanagido, Gifu-shi, Gifu 501-1193, Japan.
3
‡These authors contributed equally.
4
† Present address: Laboratory of Drug and Gene Delivery System, Faculty of Pharma-Sciences,
5
Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan.
6
§ Present address: Department of Pharmaceutical Informatics, Graduate School of Biomedical
7
Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki 852-8588, Japan.
8
ǁ Present address: Faculty of Pharmaceutical Sciences, Aomori University, 2-3-1 Kobata,
9
Aomori-shi, Aomori 030-0943, Japan.
10 11
*Corresponding Authors: Mitsuru Hashida, Ph.D. Phone: +81-75-753-4525. Fax: +81-75-753-
12
4575. E-mail:
[email protected]; Makoto Kiso, Ph.D. Phone: +81-58-293-2916.
13
Fax: +81-58-293-2918.
E-mail:
[email protected] 14
ACS Paragon Plus Environment
2
Page 3 of 37
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
Molecular Pharmaceutics
ABSTRACT
2
Sialyl LewisX (sLeX) is a natural ligand of E-selectin that is overexpressed by inflamed
3
and tumor endothelium. Although sLeX is a potential ligand for drug targeting, synthesis of the
4
tetrasaccharide is complicated with many reaction steps. In this study, structurally simplified
5
novel
6
phosphoethanolamine-polyethyleneglycol-2000 (DSPE-PEG) for E-selectin-mediated liposomal
7
delivery. The sLeX structural simplification strategies include (1) replacement of the Gal-
8
GlcNAc disaccharide unit with lactose to reduce many initial steps and (2) substitution of
9
neuraminic acid with a negatively charged group, i.e., 3'-sulfo, 3'-carboxymethyl (3'-CM), or 3'-
10
(1-carboxy)ethyl (3'-CE). While all the liposomes developed were similar in particle size and
11
charge, the 3'-CE sLeX mimic liposome demonstrated the highest uptake in inflammatory
12
cytokine-treated human umbilical vein endothelial cells (HUVECs), being even more potent than
13
native sLeX-decorated liposomes. Inhibition studies using anti-selectin antibodies revealed that
14
their uptake was mediated primarily by overexpressed E-selectin on inflamed HUVECs.
15
Molecular dynamics simulations were performed to gain mechanistic insight into the E-selectin
16
binding differences among native and mimic sLeX. The terminally branched methyl group of the
17
3'-CE sLeX mimic oriented and faced the bulk hydrophilic solution during E-selectin binding.
18
Since this state is entropically unfavorable, the 3'-CE sLeX mimic molecule might be pushed
19
toward the binding pocket of E-selectin by a hydrophobic effect, leading to a higher probability
20
of hydrogen-bond formation than native sLeX and the 3'-CM sLeX mimic. This corresponded
21
with the fact that the 3'-CE sLeX mimic liposome exhibited much greater uptake than the 3'-CM
22
sLeX mimic liposome.
sLeX
analogs
were
designed
and
linked
with
1,2-distearoyl-sn-glycero-3-
ACS Paragon Plus Environment
3
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 4 of 37
1
KEYWORDS: targeted liposomal delivery; inflamed endothelial cell; E-selectin; sialyl LewisX
2
mimic; in vitro uptake; molecular dynamics simulation
3
ACS Paragon Plus Environment
4
Page 5 of 37
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
FOR TABLE OF CONTENTS USE ONLY
2
Title: Synthesis and functional characterization of novel sialyl LewisX mimic-decorated
3
liposomes for E-selectin-mediated targeting to inflamed endothelial cells.
4
Authors: Chanikarn Chantarasrivong, Akiharu Ueki, Ryutaro Ohyama, Johan Unga, Shinya
5
Nakamura, Isao Nakanishi, Yuriko Higuchi, Shigeru Kawakami, Hiromune Ando, Akihiro
6
Imamura,
Hideharu
Ishida,
Fumiyoshi
Yamashita,
Makoto
Kiso,
Mitsuru
Hashida
7 8 9
ACS Paragon Plus Environment
5
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
Page 6 of 37
INTRODUCTION
2 3
E-selectin is a transmembrane glycoprotein that is expressed in endothelial cells. Its expression
4
is extremely low in resting endothelial cells, but it is strongly induced via transcriptional
5
regulation by inflammatory cytokines such as TNFα and IL-1β.1, 2, 3 The physiological function
6
of E-selectin is to support leukocyte tethering and rolling on specific locations of the
7
endothelium and allow for further strong integrin-mediated interactions. Leukocytes recruited at
8
the site of inflamed tissues remove pathogens and cellular debris and produce growth factors for
9
tissue repair. Therefore, the expression of E-selectin is involved as an initial trigger in
10
attenuating acute inflammatory injury. However, it is also known that the same mechanism
11
occurs during the development of tumor tissues.4, 5, 6 Cancer cells and tumor stroma produce
12
cytokines to activate the vascular endothelium, recruit and tame innate immune cells, and form a
13
robust immunosuppressive network called the tumor microenvironment.
14
Augmented expression of E-selectin in endothelial cells at inflamed or tumor tissues is an
15
attractive option for targeted delivery of specific drugs to these tissues. As has been reviewed
16
elsewhere,7,
17
polymer-based nanoparticles decorated with anti-E-selectin antibodies and small molecular
18
ligands, have been designed and functionally characterized. Studies on immunoliposomes
19
bearing anti-E-selectin antibodies were conducted a relatively long time ago. The first
20
demonstration of this concept was undertaken by Bendas et al. in 1998,11 and was later expanded
21
by their group and other groups.12, 13, 14, 15 However, sialyl LewisX (sLeX, Neu5Acα2-3Galβ1-
22
4(Fucα1-3)GlcNAcβ) tetrasaccharide-decorated nanoparticles have also been studied.16, 17, 18, 19
23
sLeX is a naturally occurring E-selectin ligand and is found at the terminus of N- or O-glycans
8, 9, 10
several types of E-selectin-directed drug delivery systems, i.e., lipid- or
ACS Paragon Plus Environment
6
Page 7 of 37
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
and glycolipids on the surface of leukocytes and tumor cells. Use of such a small molecular
2
ligand is beneficial due to lower immunogenicity compared with the use of immunoliposomes.20,
3
21
4
demonstrated to be highly accessible delivery vehicles for E-selectin targeting both in vitro and
5
in vivo,22, 23, 24, 25, 26, 27 their availability is hampered by the complexity and difficulty of sLeX
6
synthesis. The large-scale production of sLeX is costly, requires considerable technical expertise,
7
and involves many synthesis steps.28,
8
development of structurally simplified analogs of sLeX (so-called sLeX mimics) is promising.
However, although sLeX-decorated liposomes and nanoparticles have successfully been
29, 30, 31
To overcome these drawbacks, the design and
9
The details of sLeX-selectin binding have been investigated in both functional and structural
10
studies. Systematic replacement of the functional groups of sLeX with hydrogen revealed that all
11
three OH groups of the Fuc, the 4- and 6-OH groups of the Gal, and the COO– group of the
12
NeuAc are required for sLeX to bind to E- and L-selectins.32, 33 In addition, it has also been
13
reported that the GlcNAc residue does not play a crucial role in binding. Crystallographic
14
analysis of E-selectin and sLeX cocrystals supports the results of functional studies.34, 35, 36 The
15
3- and 4-OH groups of the Fuc form a network of interactions with the selectin-bound Ca++ ion
16
and several amino acid residues, while the 4- and 6-OH groups of the Gal and the COO– group of
17
the NeuAc are responsible for further hydrogen-bond formation. Accordingly, substitution of
18
NeuAc with a negatively charged group, such as carboxymethyl, sulfate, and phosphate groups,
19
on the 3' position of the Gal would be the most straightforward way to simplify the structure of
20
sLeX.37, 38, 39 Taking into account that the GlcNAc residue is not responsible for binding, we
21
previously proposed and demonstrated the feasibility of fucosylated 3'-sulfo-lactose as a potent
22
and convenient sLeX mimic.40 Replacement of the Gal-GlcNAc disaccharide unit with lactose
23
(i.e., Gal-Glc) removes many initial steps.
ACS Paragon Plus Environment
7
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 8 of 37
1
Based on reported structure-activity studies of sLeX and its mimics,32, 40, 41, 42 the present study
2
was initiated to develop novel glycolipids that are available for E-selectin-targeted drug carriers.
3
We conjugated sLeX and its mimics with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
4
polyethyleneglycol-2000 (DSPE-PEG), taking into account that the swollen layers formed with
5
PEG chains are required for steric protection of particulate drug carriers.43, 44, 45, 46 In the present
6
study, three fucosylated lactose derivatives modified on the 3' position of the lactose unit, i.e., 3'-
7
sulfo, 3'-carboxymethyl (3'-CM), and 3'-(1-carboxy)ethyl (3'-CE), were synthesized as sLeX
8
mimics. On the basis of previous results of sLeX mimic development,40, 47 we expected that
9
fucosylated 3'-sulfo-lactose would be a suitable targeting motif because of its binding affinity to
10
E-selectin. The 3'-CM and 3'-CE analogs were newly designed as more chemically stable
11
analogs than the 3'-sulfo (Scheme 1). These analogs retain the position of the COO– group of
12
NeuAc within sLeX and are expected to engage in hydrogen-bond formation similar to sLeX. In
13
addition, the 3’-CE analog was anticipated to provide strong interaction to E-selectin because the
14
methyl group of the 3'-CE group limits the free rotation of the COO– group. The most interesting
15
finding in this study is that 3'-CE sLeX mimic liposomes, which are newly developed, exhibit
16
greater and more specific uptake than native sLeX in cytokine-activated human umbilical vein
17
endothelial cells (HUVECs). The molecular mechanisms underlying the binding of sLeX mimics
18
with E-selectin were confirmed by molecular dynamics simulations using the structure of the
19
sLeX-E-selectin cocrystal (PDB: 4CSY) as a template.
20 21 22
EXPERIMENTAL SECTION
23
ACS Paragon Plus Environment
8
Page 9 of 37
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
Molecular Pharmaceutics
1. Outline of the synthesis of sLeX mimic‐linked phospholipids
2
The targeting motifs were synthesized using an efficient, stereoselective route (Scheme 1).
3
First, 3-aminopropyl lactoside 1 was prepared according to a previously reported procedure,48
4
and it was then converted into the mono-hydroxy form 2 through a four-step reaction sequence.
5
Next, compound 2 underwent α-selective fucosylation with donor 3 with the assistance of the
6
synergistic solvent effect of CPME-CH2Cl2,49 followed by replacement of the MBn group with
7
an acetyl group and the acid hydrolysis of the isopropylidene group at C3' and C4', producing 4.
8
3'-OH selective sulfonylation, carboxymethylation and 1-carboxyethylation via tin acetal
9
formation and subsequent full deacylation produced 3'-sulfo and 3'-carboxymethyl and 3'-(1-
10
carboxy)ethyl trisaccharides, respectively. Finally, they were conjugated with DSPE-PEG to
11
create sLeX mimic targeting motifs 5, 6 and 7, respectively.
12
13 14 15 16 17 18
Scheme 1. Synthesis of sLeX mimic-linked phospholipids. (a) CSA/2,2-dimethoxypropane, acetone, MeCN, RT, 1 d, 63%; (b) H2, 5% Pd/C/1,4-dioxane-H2O (2:1), RT, 6 h; (c) TFAOMe, Et3N/MeOH, RT, 4 h, 89% (2 steps); (d) BzCl/toluene-pyridine (4:3), 0°C, 1.5 h, 64%; (e) 3, NIS, TfOH, MS4Å/CPME-CH2Cl2 (1:1), -40°C, 1 d; (f) DDQ/CH2Cl2-H2O (10:1), RT, 6 h; (g) Ac2O/pyridine, RT, 2 h, 49% (3 steps); (h) 80% TFAOH aq./CH2Cl2, 0°C, 0.5 h, 98%; (i) i.
ACS Paragon Plus Environment
9
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1 2 3 4 5 6 7 8 9 10 11 12
Page 10 of 37
nBu2SnO/toluene, reflux, 5 h; ii. SO3·NMe3/THF-DMF (4:1), RT, 15 h, 88% (2 steps); iii. 1 M NaOH aq./MeOH, RT, 21 h; iv. DSPE-PEG2000-NHS /DMF-H2O (4:1), RT, 1 h, 80% (2 steps); (j) i. nBu2SnO/toluene, reflux, 5 h; ii. ethyl bromoacetate, nBu4NI/toluene, 80°C, 5 h; iii. Ac2O, DMAP/pyridine, RT, 6 h; iv. 1 M NaOH aq./MeOH, RT, 18 h; v. DSPE-PEG2000-NHS /DMFH2O (4:1), RT, 1 h, 49% (5 steps); (k) i. nBu2SnO/toluene, reflux, 5 h; ii. BrCH(Me)CO2Et, nBu4NBr/toluene, 100°C, 3 h; iii. Ac2O, DMAP/pyridine, RT, 3 h, 44% (2 steps); iv. 1 M NaOH aq./MeOH, RT, 2 h; v. DSPE-PEG2000-NHS, Me3N/DMF-H2O (3:1), RT, 1 h, 31% (2 steps). Cbz = benzyloxycarbonyl; TFA = trifluoroacetyl; Bz = benzoyl; MBn = p-methoxybenzyl; CSA = 10-comphorsulfonic acid; NIS = N-iodosuccinimide; CPME = cyclopentyl methyl ether; DDQ = 2,3-dichloro-5,6-dicyanobenzoquinone; DMF = N,N-dimethylformamide; DMAP = 4dimethylaminopyridine; DSPE-PEG = 1,2-distearoyl-sn-glycero-3-phosphoethanolaminepolyethyleneglycol-2000; NHS = N-hydroxysuccinimidyl.
13 14
Detailed experimental procedures for synthesizing the target compounds and spectroscopic
15
data for structural determination of newly synthesized compounds are described in Supporting
16
Information, section S1.
17 18
2. Preparation of liposomes
19
1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) was purchased from Avanti Polar Lipids
20
(Alabaster, AL). Cholesterol, methanol, and chloroform were purchased from Nacalai Tesque
21
(Kyoto, Japan). DSPE-PEG-Fluorescein was prepared through the chemical reaction of DSPE-
22
PEG-NH2 (NOF America Corporation, White Plains, NY) and Fluorescein-NHS (Thermo Fisher
23
Scientific, Waltham, MA) following the protocol supplied by the manufacturer. DSPC (2.75
24
µmol/mL), cholesterol (1.95 µmol/mL), native sLeX- or sLeX mimic-linked DSPE-PEG (0.25
25
µmol/mL) and DSPE-PEG-Fluorescein (0.05 µmol/mL) were individually dissolved in
26
chloroform-methanol (1:1). One milliliter of each solution was mixed in a 50-mL round-bottom
27
flask. The solvent of the mixture was removed under reduced pressure using a rotary evaporator.
28
The resultant lipid film was further vacuum-desiccated for at least 6 h. The lipid film was
29
swollen using phosphate-buffered saline (PBS, Nissui Pharmaceutical, Tokyo, Japan) at room
ACS Paragon Plus Environment
10
Page 11 of 37
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
temperature for 30 min and suspended by shaking for 30 min in a water bath at 65°C. The
2
suspension was sonicated in a bath-type sonicator (ASU-3M, AS ONE, Osaka, Japan) at 65°C
3
for 10 min and then a tip-type sonicator (Ultrasonic generator US 300, Nissei, Tokyo, Japan) at
4
an intensity of 200 W for 3 min. The suspension was then extruded 31 times through a 100-nm
5
pore membrane equipped in an extruder (Avanti Mini-Extruder, Avanti Polar Lipids, Alabaster,
6
AL) maintained at 65°C. The liposome solution was purified using a NAP-5 gel filtration column
7
(GE Healthcare, Buckinghamshire, UK) equilibrated with PBS. After the amount of
8
phospholipids in the eluate was determined using a Phospholipids C-test Wako (Wako Pure
9
Chemical Industry), the liposome concentration was adjusted to 500 nmol total lipid/mL. An
10
aliquot of the stock solution was diluted 2.5 times with distilled water, and 750 µL of the
11
solution was taken for measurement of the particle size and zeta potential of the liposomes in a
12
Zetasizer Nano ZS (Malvern, Worcester, UK). Moreover, the fluorescence intensity of each
13
liposome was determined at a total lipid concentration of 1 nmol/mL using a Fluoromax-4
14
spectrofluorometer (Horiba, Kyoto, Japan).
15 16
3. Evaluation of the cellular uptake of liposomes
17
HUVECs were purchased from Kurabo Industry (Osaka, Japan) and cultured according to the
18
protocol supplied by the manufacturer. HuMedia-EG2 (Kurabo, Osaka, Japan) was used as the
19
culture medium. The cells were harvested, suspended in the culture medium, and plated at a
20
density of 100,000 cells/0.5 mL in a 24-well plate on the day before experiments. Prior to uptake
21
experiments, TNF-α (Life Technologies, Carlsbad, CA) and IL-1β (Sigma Aldrich, St. Louis,
22
MO) were added to the medium at a final concentration of 100 ng/mL and 10 ng/mL,
23
respectively, and the cells were incubated for another 5 h. At the onset of the uptake
ACS Paragon Plus Environment
11
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 12 of 37
1
experiments, the culture medium was replaced with medium containing fluorescein-labeled
2
liposomes (50 nmol total lipid/mL). Following incubation for the indicated time periods, the cells
3
were washed with PBS and incubated with 0.3 mL of 0.0025% trypsin for 3–5 min at room
4
temperature. The cells were then centrifuged and resuspended in 0.2 mL of ice-cold PBS. Flow
5
cytometry analysis was conducted using a FACSCanto II (BD Biosciences, San Jose, CA) with
6
excitation and emission wavelength settings of 494 and 519 nm, respectively. Ten thousand gated
7
cells were analyzed using a fluorescence histogram with the BDFACSDiva software program.
8 9
4. Inhibition of the cellular association of liposomes by anti-selectin antibodies
10
HUVECs were harvested, suspended in the culture medium, and plated at a density of 40,000
11
cells/0.25 mL in a 48-well plate on the day before the experiments. Prior to the experiments, the
12
cells were pretreated with 100 ng/mL TNF-α and 10 ng/mL IL-1β for 5 h. The culture medium
13
was replaced with an equal volume of Hank's buffered salt solution (HBSS) (Nissui
14
Pharmaceutical, Tokyo, Japan) containing one of the anti-selectin antibodies (Abcam,
15
Cambridge, UK) at a concentration of 10 µg/mL, and the cells were then incubated for 30 min on
16
ice. Twenty-five microliters of 500 nmol total lipid/mL liposome solution was added at the onset
17
of the cellular association study. Fifteen minutes later, the cells were washed twice with 0.3 mL
18
of HBSS supplemented with 10% fetal bovine serum (FBS) and once with 0.3 mL of HBSS and
19
then lysed with 0.1 mL of an aqueous lysis buffer composed of 0.05% Triton X-100, 0.075%
20
EDTA, and 1.21% Tris for 15 min on a shaker. The lysates were transferred to a 96-well plate,
21
and their fluorescence intensity was determined using an ARVO MX microplate fluorometer
22
(Perkin Elmer, Waltham, MA) with excitation-emission wavelengths set at 485 and 535 nm,
23
respectively. The protein concentration in 20-µL aliquots of the lysate was measured using the
ACS Paragon Plus Environment
12
Page 13 of 37
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
Protein Quantification Kit-Wide Range (Dojindo Molecular Technologies, Rockville, MD). In
2
addition, the inhibitory effects of anti-selectin antibodies were statistically evaluated using a one-
3
way analysis of variance with Dunnett’s post hoc test.
4 5
5. Confocal fluorescence microscopy analysis of the subcellular distribution of liposomes
6
HUVECs were harvested, suspended in the culture medium, and plated at a density of 40,000
7
cells/0.25 mL in an 8-well chamber slide on the day before the experiments. Prior to uptake
8
experiments, TNF-α and IL-1β were added to the medium at a final concentration of 100 ng/mL
9
and 10 ng/mL, respectively, and the cells were incubated for another 5 h. At the onset of the
10
uptake experiments, the culture medium was replaced with medium containing fluorescein-
11
labeled liposomes (50 nmol total lipid/mL). After incubating for 3 h, the cells were washed 3
12
times with PBS and fixed with 4% paraformaldehyde phosphate buffer solution (Nacalai Tesque,
13
Kyoto, Japan). Fifteen minutes later, the cells were washed with PBS, mounted with Vectashield
14
mounting medium containing DAPI (Vector laboratories Inc, Burlingame, CA), and observed
15
using a confocal microscope (Nikon A1RMP/Ti-E/PFS, Nikon Instruments Inc., Melville, NY)
16
equipped with NIS-elements AR 4.13.00 software. The excitation wavelength was set at 488.5
17
nm and 404 nm, and the emission wavelengths were scanned in the range of 500-550 nm and
18
425-475 nm for fluorescence and DAPI, respectively.
19 20
6. Molecular dynamics simulation
21
The structure of the sLeX-E-selectin cocrystal (PDB: 4CSY)50 was used as a template to
22
investigate the molecular binding of sLeX mimics with E-selectin. A molecular dynamics (MD)
23
calculation of the solvated protein-ligand complex was performed using the GROMACS 5.0.4
ACS Paragon Plus Environment
13
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 14 of 37
1
package.51 The AMBER-ff99SB force field52 and the AMBER-GAFF53/AM1-BCC54 were
2
assigned for E-selectin and ligand molecules, respectively. Each complex structure was
3
neutralized and placed in a TIP3P55 water box, with a margin of 10 Å between the protein and
4
the boundaries of the periodic box. The particle mesh Ewald method with a cut-off of 8 Å was
5
used to calculate long-range electrostatic interactions. MD simulations of 100 ps for the system
6
relaxation under constant NVT conditions at 300 K and 400 ps for water molecule density
7
equilibration under constant NPT conditions at 1 bar and 300 K were performed before data
8
collection. Subsequently, an MD simulation of 2 ns was performed under constant NVT
9
conditions at 300 K, and the complex structures were extracted in the 201 snapshots taken every
10
10 ps. This MD simulation scheme was replicated three times, and the analyses for hydrogen-
11
bond formations and distributions of dihedral angles were performed in a total of 603 snapshots.
12 13 14
RESULTS
15 16
1. Physicochemical characteristics of native and mimic sLeX liposomes
17
Table 1 summarizes the particle size and zeta potential of the prepared liposomes. The average
18
diameter was similar in all the liposomes, ranging from 96.4 to 106.4 nm. Their polydispersity
19
indices were no more than 0.19, indicating that liposomes with a uniform size distribution were
20
obtained by employing an extrusion method following the hydration-sonication method.
21
Whereas the PEG liposome was nearly neutral with a zeta potential of −6.92 ± 1.23 mV, all
22
liposomes bearing the native or mimic sLeX residues were highly negative with regard to surface
23
charge, but the negative charges associated with native or mimic sLeX were not significantly
ACS Paragon Plus Environment
14
Page 15 of 37
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
different. The fluorescence intensities of all prepared liposomes were comparable but, to be more
2
precise, were employed for normalization of cellular uptake.
3 4 5
6 7 8
Table 1. Physicochemical characteristics of native and mimic sLeX liposomes Liposomea)
Average diameter (nm)
PDIb)
Zeta potential (mV)
PEG
102.53 ± 0.46
0.16
–6.92 ± 1.23
Native sLeX-PEG
98.45 ± 1.01
0.16
–24.5 ± 1.1
3'-sulfo sLeX mimic-PEG
106.37 ± 1.46
0.19
–23.97 ± 0.85
3'-CM sLeX mimic-PEG
96.35 ± 0.51
0.17
–23.03 ± 1.7
3'-CE sLeX mimic-PEG
102.33 ± 0.71
0.11
–24.70 ± 1.1
a) PEG, polyethylene glycol; 3'-CM, 3'-carboxymethyl; 3'-CE, 3'-(1-carboxy)ethyl. b) PDI, polydispersity index.
9 10
2. Uptake in cytokine-treated HUVECs
11
Figure 1A shows the time course of the uptake of native and mimic sLeX liposomes in
12
proinflammatory cytokine-treated HUVECs. The cellular uptake of all tested liposomes
13
increased linearly over 4 h. The uptake rate calculated from the slope was highest with the 3'-CE
14
sLeX mimic liposomes (105.2-fold higher than that of the PEG liposome), followed by the 3'-
15
sulfo sLeX mimic (90.1-fold), native sLeX (85.1-fold), and 3'-CM sLeX mimic liposomes (25.5-
16
fold). Hereafter, the cellular uptake of the liposomes was evaluated at 3 h.
17
Figure 1B shows the concentration dependence of the liposome uptake. The uptake of native
18
and mimic sLeX liposomes obeyed nonlinear kinetics within the concentration range tested
19
(0.025–0.2 µmol total lipid/mL). The Eadie–Hofstee plot analysis indicated that the Michaelis–
20
Menten constants (Km) were 0.011, 0.020, 0.025, and 0.057 µmol total lipid/mL for the 3'-CE
ACS Paragon Plus Environment
15
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 16 of 37
1
sLeX mimic, native sLeX, 3'-sulfo sLeX mimic, and 3'-CM sLeX mimic liposomes, respectively
2
(Figure 2). The order of the affinity-related constant values corresponded to that of the uptake
3
rate.
4 5
6 7 8 9 10 11
Figure 1. Time-course analyses (A) and concentration dependence (B) of the uptake of fluorescein-labeled liposomes in HUVECs treated with TNF‐α and IL‐1β for 5 h. Symbols: , PEG liposome; , native sLeX liposome; , 3'-sulfo sLeX mimic liposome; , 3'-CM sLeX mimic liposome; , 3'-CE sLeX mimic liposome.
ACS Paragon Plus Environment
16
Page 17 of 37
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1 2 3 4 5 6
Molecular Pharmaceutics
Figure 2. Eadie–Hofstee diagrams of the uptake of (A) native sLeX, (B) 3'-sulfo sLeX mimic, (C) 3'-CM sLeX mimic, and (D) 3'-CE sLeX mimic liposomes in HUVECs pretreated with 100 ng/mL TNF-α and 10 ng/mL IL-1β for 5 h. The ordinate and abscissa represent the uptake rate (v) and the uptake rate divided by liposome concentration (v/s), respectively. The regressed equation, together with its regression coefficient, is shown in each panel, where
ACS Paragon Plus Environment
17
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1 2
Page 18 of 37
v v = −Km ⋅ + Vmax s
3
To elucidate involvement of specific uptake processes, the effect of specific antibodies on the
4
cellular association of the liposomes was investigated. Figure 3 shows the cellular association of
5
native and mimic sLeX liposomes in the presence and absence of specific antibodies against E-
6
selectin, P-selectin, or L-selectin (10 µg/mL). The anti-E-selectin antibody inhibited the cellular
7
association of native sLeX, 3'-sulfo sLeX mimic, and 3'-CE sLeX mimic liposomes by 70%,
8
72.7%, and 91.7%, respectively, whereas significant inhibition did not occur for the 3'-CM sLeX
9
mimic liposome. In contrast, neither the anti-P-selectin nor anti-L-selectin antibodies affected the
10
cellular association of any of the liposomes. Therefore, the uptake of native and mimic sLeX
11
liposomes was considered to be mediated mostly by E-selectin, the expression of which was
12
upregulated by pretreatment with TNF-α and IL-1β.
13 14 15
Figure 3. Inhibition by anti‐selectin antibodies of the association of fluorescein‐labeled native and mimic sLeX liposomes with HUVECs treated with TNF‐α and IL‐1β. *P